Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Mazdutide
An educational, source-based comparison of Dulaglutide (Trulicity) and Mazdutide — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
A dual agonist of GLP-1 and glucagon receptors, similar to survodutide. The glucagon component increases energy expenditure while GLP-1 suppresses appetite and improves glycemic control.
- Chronic weight management
- Type 2 diabetes
- MASH / NAFLD
- • Investigational; not FDA-approved.
- • Glucagon agonism may affect heart rate and blood pressure.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Dulaglutide (Trulicity) | REWIND trial | Lancet | 2019 | Reduced major adverse cardiovascular events in T2D patients with or without prior CV disease. |
| Mazdutide | Mazdutide for obesity: Phase 2 results | The Lancet Diabetes & Endocrinology | 2024 | Achieved ~15% mean weight loss at 48 weeks with manageable side effects. |
Side-effect & safety grid
- FDA-approved.
- Boxed warning: thyroid C-cell tumors in rodents.
- Investigational; not FDA-approved.
- Glucagon agonism may affect heart rate and blood pressure.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Dulaglutide (Trulicity) vs Mazdutide — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Mazdutide is Metabolic · Incretin.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Mazdutide — chronic weight management.
- Tag: FDA-Approved · Metabolic vs Weight loss.